HK Stock Market Move | PEIJIA-B(09996) rises over 3% as the registration application for the GeminiOne transcatheter edge-to-edge repair system is approved by the National Medical Products Administration.

PEIJIA-B(09996) rose over 3%, up 3.04% as of press time, at HK$4.915, with a turnover of HK$3.1693 million. On the news front, on September 11, PEIJIA-B announced that the registration application for its self-developed GeminiOne transcatheter edge-to-edge repair ("TEER") system ("GeminiOne") has recently been approved by the National Medical Products Administration of the People's Republic of China ("NMPA"). The approval of GeminiOne marks the Group's official entry into the commercial treatment field of mitral regurgitation, and represents a further significant expansion of its transcatheter valve therapy product portfolio on the basis of its existing layout in the treatment of aortic stenosis and aortic regurgitation. Regarding the EU MDR CE mark registration application and the U.S. early feasibility study for GeminiOne. The EU MDR CE mark registration application for GeminiOne has been submitted, and the U.S. early feasibility study is currently underway.